The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND:nab‐Paclitaxel (ABI‐007, Abraxane), a 130‐nM, albumin‐bound (nab) particle form of Cremophor‐free paclitaxel, is approved for metastatic breast cancer. In the current study, the efficacy and safety of nab‐paclitaxel were evaluated in previously treated and chemotherapy‐naive patients with metastatic melanoma (MM).
METHODS:Patients with histologically or cytologically confirmed, measurable...
BACKGROUND:Because of their rarity, no prospective studies have been performed regarding gangliogliomas. The optimal treatment regimen is unclear. In this study, the authors compared 4 therapies for local control (LC) and overall survival (OS) in patients with ganglioglioma.
METHODS:In 402 patients with ganglioglioma, outcomes were compared for patients who underwent gross total resection alone (GTR)...
BACKGROUND:Although chemotherapy and radiation therapy currently are recommended in limited‐stage small cell lung cancer (L‐SCLC), several small series have reported favorable survival outcomes in patients who underwent surgical resection. The authors of this report used a US population‐based database to determine survival outcomes of patients who underwent surgery.
METHODS:The Surveillance, Epidemiology,...
BACKGROUND:Gefitinib and erlotinib are commonly used for salvage therapy in patients with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although both agents have similar structure and have demonstrated efficacy in NSCLC, gefitinib and erlotinib have not been directly compared in terms of efficacy and other clinical outcomes in patients with NSCLC who have failed prior chemotherapy...
BACKGROUND:Altered glucose metabolism is the most common metabolic hallmark of malignancies. The authors tested the hypothesis that glucose metabolism gene variations affect clinical outcome in pancreatic cancer.
METHODS:The authors retrospectively genotyped 26 single nucleotide polymorphisms from 5 glucose metabolism genes in 154 patients with localized disease and validated the findings in 552...
BACKGROUND:Lung cancer is the leading cause of cancer‐related deaths worldwide. Epigenetic inactivation of certain genes by aberrant promoter methylation is recognized as a crucial component in the initiation and progression of lung cancer. Response gene to complement 32 (RGC32) has been identified as a cell cycle regulator induced by activation of complements; however, its role in carcinogenesis...
BACKGROUND:Reporting of randomized controlled clinical trials (RCTs) often is suboptimal. Cancer drug trials are complicated further by multiple survival and response endpoints. The authors of this report determined the frequency of reporting of time‐to‐event endpoints and tumor response outcomes in advanced colorectal cancer and examined the relation between the year of publication and the reported...
BACKGROUND:An important goal of noncurative therapy for metastatic renal cell carcinoma (mRCC) is tumor burden (TB) control. However, to the authors' knowledge, the impact of TB characteristics on clinical outcome has not been studied in patients with mRCC who were treated with vascular endothelial growth factor‐targeted therapy.
METHODS:Patients with clear cell mRCC who were treated with sunitinib...
BACKGROUND:In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM).
METHODS:The authors analyzed the prognostic value of deletion del(13q14), del(17p13), +1q21, translocation t(4;14), t(11;14), and t(14;16) by fluorescence in situ hybridization...
BACKGROUND.The majority of metastatic renal cell carcinoma (mRCC) clinical trials that examined targeted agents used progression‐free survival (PFS) as the primary endpoint. Whether PFS can be used as a predictor of overall survival (OS) is unknown.
METHODS.Patients from 12 cancer centers who received targeted therapy for mRCC were identified. Landmark analyses for progression at 3 months and 6 months...
BACKGROUND:In men with metastatic castration‐resistant prostate cancer (CRPC), the association of measurable tumor responses with overall survival (OS) is unknown. The authors retrospectively evaluated the TAX327 phase 3 trial to study this relation.
METHODS:Eligible patients for this analysis included those with World Health Organization (WHO)‐defined measurable metastatic disease randomized to...
The authors undertook a systematic review to designate the role that radiotherapy (RT) might play in the treatment of retroperitoneal sarcomas. Correlating with recent literature, the objective of this review was to evaluate whether there was enough evidence for the authors to develop an institutional treatment protocol concerning the use of RT in the treatment of retroperitoneal sarcoma. Furthermore,...
BACKGROUND:Meningioma is the most common extra‐axial primary intracranial tumor in adults that rarely metastasizes outside of the central nervous system (CNS). Among recognized sites of metastases, the lung is the most common, but the importance of lung metastases relative to prognosis is unknown. 111Indium (111In)‐octreotide scintigraphy (octreotide scanning) is a valuable imaging modality with which...
BACKGROUND:Metabolic imaging is of interest in esophageal cancer; however, the usefulness of initial standardized uptake value (SUV) in positron emission tomography (PET) is unknown in patients with esophageal or gastroesophageal carcinoma treated with definitive chemoradiotherapy. The authors hypothesized that initial SUV would correlate with patient outcome.
METHODS:The authors retrospectively...
BACKGROUND:The authors conducted a retrospective study to evaluate the effects of thoracic radiation therapy (TRT) for patients with extensive‐stage small cell lung cancer (ED‐SCLC).
METHODS:Between January 2003 and December 2006, the records of 119 patients who were diagnosed with ED‐SCLC (all with distant metastasis [M1]) were included in the study. Sixty patients received chemotherapy (ChT) and...
BACKGROUND:Refractory germ cell tumor (GCT) patients have a poor prognosis and limited treatment options. The identification of novel active agents may be impaired by use of response as the primary endpoint in phase 2 trials. Improved endpoints could enhance the development of new effective agents.
METHODS:The characteristics and outcome of refractory GCT patients enrolled in 7 single‐agent phase...
BACKGROUND:Tobacco use is a leading cause of premature death, yet few studies have investigated the effect of tobacco exposure on the outcome of patients with renal cell carcinoma (RCC). The authors of this report retrospectively studied the impact of smoking on clinicopathologic factors, survival outcomes, and p53 expression status in a large cohort of patients with RCC.
METHODS:Eight hundred‐two...
BACKGROUND:The purpose of this study was to investigate the overall survival (OS) of patients with advanced ALK‐positive nonsmall cell lung cancer (NSCLC) who were managed in the pre‐ALK inhibitor era and to compare their survival with that of a matched case cohort of ALK wild‐type (WT) patients.
METHODS:Data from 1166 patients who had stage IIIB/IV NSCLC with nonsquamous histology were collected...
BACKGROUND:Patients with brain metastases who have a favorable survival prognosis may benefit from intensive treatments, including neurosurgery and radiosurgery. However, many patients cannot receive such treatments, and whole‐brain radiotherapy (WBRT) alone is their only option. The most common WBRT schedule is 30 grays (Gy) in 10 fractions. In this retrospective study, the authors investigated whether...
BACKGROUND:Pulmonary lymphoepithelioma‐like carcinoma (LELC) is a rare kind of cancer.
METHODS:In this study, the authors evaluated 52 patients with pulmonary LELC who had long‐term follow‐up. Clinical characteristics, tumor markers, epidermal growth factor receptor (EGFR) mutation status, treatments, and outcomes were analyzed.
RESULTS:Pulmonary LELC mostly affected young, nonsmoking patients....
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.